While medications or Botox® injections can be effective in reducing symptoms for several months, they require repeated treatments and refills. In fact, studies show that many people discontinue these treatments over time.1,2 As a result, many people continue to struggle with their symptoms.
80%
of people with Overactive Bladder (OAB) discontinue their incontinence medications within 1 year.2
60%
of people with OAB discontinue Botox treatment after 2-3 injections.1
Lasting relief is possible with Axonics® Therapy
Axonics Therapy is a safe, long-term treatment known as Sacral Neuromodulation that helps restore communication between the brain, bladder and bowel. Advantages of Axonics Therapy include:
Axonics Therapy lasts 10-20 years* unlike injections that are required every 6 months.3
Axonics Therapy is clinically proven to provide lasting relief, and 94% of patients report satisfaction with their therapy.3
You can test out Axonics Therapy first to see if it provides relief.
Take the Quiz
to find out if Axonics Therapy or Bulkamid may be right for you.
If you're tired of repeated Botox® injections, due to side effects or insufficient symptom relief, you owe it to yourself to speak with an expert physician.
![Over 60% Discontinue Botox Treatment after 2 - 3 injections [1]](assets/images/over-60-botox.png)
![Over 60% Discontinue Botox Treatment after 2 - 3 injections [1]](assets/images/m-over-60-botox.png)
8 out
of 10
people who received Axonics Therapy after discontinuing Botox® preferred Axonics Therapy.4
*depending on therapy settings
Axonics Therapy can offer 20+ years of relief.* In this span, a Botox patient would have to undergo 40 procedures for repeat injections.5
After trying many alternatives, I could not be happier with my Axonics Therapy. It has brought me the relief I was searching for.
Jill | Real Axonics Therapy PatientResults and experiences may vary and are unique to each patient.
Take the first step toward real relief:
Take this short quiz to get started and see whether Axonics Therapy or Bulkamid may be right for you.
References:
Botox® is a registered trademark or Allergan, Inc.
IMPORTANT SAFETY INFORMATION:
Indications: Axonics SNM Therapy for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments. Axonics SNM Therapy for bowel control is indicated for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.
Contraindications: Axonics SNM Therapy is contraindicated for patients who have not demonstrated an appropriate response to test stimulation; or Patients who are unable to operate the Axonics SNM Systems.
Warnings: Implantation and use of the Axonics Systems incur risks beyond those normally associated with surgery, some of which may necessitate surgical intervention. These risks include, but are not limited to adverse change in voiding function (bowel and/or bladder), infection, pain or irritation at the implant site, lead or device migration, electrical shock, change in sensation or magnitude of stimulation which has been described as uncomfortable (jolting or shocking) by some patients, and heating or burns at the device site.
For more safety information about indications and potential risks, go to www.axonics.com/isi.
Precautions: The safety and effectiveness of Axonics Therapy has not been established for use in women who are pregnant or in delivery; for pediatric patients (under the age of 18 years for fecal incontinence and under the age of 16 years for overactive bladder and urinary retention); for patients with neurological diseases, such as multiple sclerosis or diabetes, or for bilateral stimulation.
Caution: U.S. Federal law restricts this device to sale and use by, or on the order of, a physician.
For a complete listing of indications, contraindications, warnings and precautions, go to www.axonics.com/isi.